Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population?

Journal of Bone and Joint Surgery - Series B

Volumn 93 B, Issue 2, 2011, Pages 251-256

  Yokote, R ^a,b   Matsubara, M ^a   Hirasawa, N ^a   Hagio, S ^a   Ishii, K ^a,b   Takata, C ^a  

^a TOHO UNIVERSITY   (Japan)

^b SAITAMA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FONDAPARINUX; PLACEBO;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; COMPRESSION BANDAGE; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; FEMALE; FOLLOW UP; HEMATOMA; HIP ARTHROPLASTY; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; JAPANESE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MECHANICAL THROMBOPROPHYLAXIS; PLACEBO EFFECT; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; COMBINED MODALITY THERAPY; COMPRESSION BANDAGES; ENOXAPARIN; FEMALE; HUMANS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; MALE; MIDDLE AGED; POLYSACCHARIDES; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; ULTRASONOGRAPHY, DOPPLER, DUPLEX; UNNECESSARY PROCEDURES; VENOUS THROMBOEMBOLISM;

EID: 79551575647     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.93B2.25795     Document Type: Article

References (27)

1. Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement: a randomised clinical trial. J Bone Joint Surg [Br] 2004;86-B:639-42.
2. Dorr LD, Gendelman V, Maheshwari AV, et al. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg [Am] 2007;89-A:2648-57.
3. Colwell CW Jr, Froimson MI, Mont MA, et al. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin. J Bone Joint Surg [Am] 2010;92-A:527-35.
4. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg [Br] 2009;91-B:636-44.
5. Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop 2008;32:443-51.
6. Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci 2008;13:442-51.
7. Buehler KO, D'Lima DD, Petersilge WJ, Colwell CW Jr, Walker RH. Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty. Clin Orthop 1999;361:123-30.
8. Sugano N, Miki H, Nakamura N, et al. Clinical efficacy of mechanical thromboprophylaxis without anticoagulant drugs for elective hip surgery in an Asian population. J Arthroplasty 2009;24:1254-7.
9. Westrich GH, Rana AJ. Prevention and treatment of thromboembolic disease: an overview. Tech Orthop 2001;16:279-90.
10. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl):338-400.
11. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl):381-453.
12. Kim YH, Kim JS. The 2007 John Charnley Award. Factors leading to low prevalence of DVT and pulmonary embolism after THA: analysis of genetic and prothrombotic factors. Clin Orthop 2007;465:33-9.
13. Parvizi J, Azzam K, Rothman RH. Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Arthroplasty 2008;23(Suppl):2-5.
14. Leizorovicz A, Turpie AG, Cohen AT, et al; SMART Study Group. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopaedic surgery without thromboprophylaxis: the SMART study. J Thromb Haemost 2005;3:28-34.
15. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
16. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997;127:895-903.
17. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997;126:638-44.
18. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
19. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997;277:1305-7.
20. Seki T, Okayama H, Kumagi T, et al. Arg605Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism. Heart Vessels 1998;13:195-8.
21. Ro A, Hara M, Takada A. The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost 1999;82:1769.
22. Balasa VV, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 1999;81:739-44.
23. Kim YN, Oh SH, Kim JS. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty: a prospective and randomised clinical study. J Bone Joint Surg [Br] 2003;85-B:661-5.
24. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular- weight heparin. and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety: Enoxaparin Clinical Trial Group. J Bone Joint Surg [Am] 1994;76-A:3-14.
25. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2199-207.
26. Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-6.
27. Pitto RP, Hamer H, Fabiani R, Radespiel-Troeger M, Koessler M. Prophylaxis against fat and bone-marrow embolism during total hip arthroplasty reduces the incidence of postoperative deep vein thrombosis: a controlled, randomized clinical trial. J Bone Joint Surg [Am] 2002;84-A:39-48.